trial

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

NCTId NCT00929370
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 34 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-07
Primary completion
2008-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Glycine Transporter-1 inhibitor

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

2 total
Glendale, United StatesBellaire, United States

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE1
Primary Completion Date
2008-10
Status
TERMINATED
relationships
The graph out of here
drug
Glycine Transporter-1 inhibitor
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication